Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myeloma

Katja Weisel • 3 Jun 2023
ASCO 2023
Multiple Myeloma Antibodies Belantamab mafodotin Dexamethasone Pomalidomide
DREAMM-3

Katja Weisel, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, briefly discusses results from the randomized Phase III DREAMM-3 trial (NCT04162210), which compared the safety of belantamab mafodotin monotherapy versus pomalidomide plus dexamethasone (pom/dex) in patients with relapsed/refractory multiple myeloma (R/R MM). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Katja Weisel

1:28
Ocular adverse events with ADCs
Katja Weisel • 10 Sep 2021
3:02
ADCs for the treatment of myeloma
Katja Weisel • 10 Sep 2021
1:43
MRD: from clinical trials to clinical practice
Katja Weisel • 10 Sep 2021
2:36
OPTIMISMM: PVd for lenalidomide-refractory myeloma
Katja Weisel • 10 Sep 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals